Comparative Pharmacology
Head-to-head clinical analysis: THEOBID versus XOPENEX HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THEOBID versus XOPENEX HFA.
THEOBID vs XOPENEX HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing cAMP, and blocking adenosine receptors. It also has anti-inflammatory and immunomodulatory effects.
Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP via activation of adenylyl cyclase.
Theophylline extended-release capsules: 300-600 mg/day orally divided every 12 hours. Initial dose 300 mg/day, titrate based on serum concentrations (target 10-20 mcg/mL). Max 600 mg/day unless serum levels monitored.
2 inhalations (90 mcg each) every 4-6 hours as needed via oral inhalation. Maximum 12 inhalations per 24 hours.
None Documented
None Documented
Neonates: 24-36 h; Children (1-9 y): 3-4 h; Adults (non-smokers): 6-12 h; Adults (smokers): 4-5 h; Hepatic cirrhosis: prolonged (up to 30 h); Heart failure: prolonged (up to 20 h).
Terminal elimination half-life: 3-4 hours; clinical context: dosing every 4-6 hours for bronchodilation
Renal (10% unchanged), hepatic metabolism (90%, primarily via CYP1A2 and CYP3A4); 20% excreted in feces as metabolites.
Renal: 80-100% as unchanged drug and metabolites; fecal: minimal (<5%)
Category C
Category C
Bronchodilator
Bronchodilator